Hunan Warrant Pharmaceutical Co. Ltd. A - Asset Resilience Ratio

Latest as of June 2025: 0.40%

Hunan Warrant Pharmaceutical Co. Ltd. A (688799) has an Asset Resilience Ratio of 0.40% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥10.00 Million
≈ $1.46 Million USD Cash + Short-term Investments

Total Assets

CN¥2.53 Billion
≈ $369.58 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2024)

This chart shows how Hunan Warrant Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. See financial agility of Hunan Warrant Pharmaceutical Co. Ltd. A to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Hunan Warrant Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688799 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥10.00 Million 0.4%
Total Liquid Assets CN¥10.00 Million 0.40%

Asset Resilience Insights

  • Limited Liquidity: Hunan Warrant Pharmaceutical Co. Ltd. A maintains only 0.40% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Hunan Warrant Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Hunan Warrant Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
JW Pharmaceutical Corp
KO:001067
Drug Manufacturers - Specialty & Generic 8.17%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
Drug Manufacturers - Specialty & Generic 14.80%
Fuan Pharmaceutical Group Co
SHE:300194
Drug Manufacturers - Specialty & Generic 1.34%
DRI Healthcare Trust
TO:DHT-U
Drug Manufacturers - Specialty & Generic 13.91%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 1.03%

Annual Asset Resilience Ratio for Hunan Warrant Pharmaceutical Co. Ltd. A (2021–2024)

The table below shows the annual Asset Resilience Ratio data for Hunan Warrant Pharmaceutical Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 7.44% CN¥183.00 Million
≈ $26.78 Million
CN¥2.46 Billion
≈ $359.92 Million
+6.75pp
2023-12-31 0.69% CN¥15.00 Million
≈ $2.19 Million
CN¥2.18 Billion
≈ $318.56 Million
-15.49pp
2022-12-31 16.18% CN¥325.00 Million
≈ $47.56 Million
CN¥2.01 Billion
≈ $293.98 Million
-6.08pp
2021-12-31 22.25% CN¥400.00 Million
≈ $58.53 Million
CN¥1.80 Billion
≈ $263.04 Million
--
pp = percentage points

About Hunan Warrant Pharmaceutical Co. Ltd. A

SHG:688799 China Drug Manufacturers - Specialty & Generic
Market Cap
$845.51 Million
CN¥5.78 Billion CNY
Market Cap Rank
#9628 Global
#2455 in China
Share Price
CN¥44.00
Change (1 day)
+0.02%
52-Week Range
CN¥40.70 - CN¥65.58
All Time High
CN¥65.58
About

Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products. It offers medicines in the areas of digestive, berating, anti-infection, gynecology, cardiovascular, cerebrovascular, immunology and nephrology, and other fields. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.